+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

Diabetes Care 32(10): 1924-1929

Although statin therapy reduces cardiovascular risk, its relationship with the development of diabetes is controversial. The first study (West of Scotland Coronary Prevention Study [WOSCOPS]) that evaluated this association reported a small protective effect but used nonstandardized criteria for diabetes diagnosis. However, results from subsequent hypothesis-testing trials have been inconsistent. The aim of this meta-analysis is to evaluate the possible effect of statin therapy on incident diabetes. A systematic literature search for randomized statin trials that reported data on diabetes through February 2009 was conducted using specific search terms. In addition to the hypothesis-generating data from WOSCOPS, hypothesis-testing data were available from the Heart Protection Study (HPS), the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), and the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), together including 57,593 patients with mean follow-up of 3.9 years during which 2,082 incident diabetes cases accrued. Weighted averages were reported as risk ratios (RRs) with 95% CIs using a random-effects model. Statistical heterogeneity scores were assessed with the Q and I(2) statistic. In the meta-analysis of the hypothesis-testing trials, we observed a small increase in diabetes risk (RR 1.13 [95% CI 1.03-1.23]) with no evidence of heterogeneity across trials. However, this estimate was attenuated and no longer significant when the hypothesis-generating trial WOSCOPS was included (1.06 [0.93-1.25]) and also resulted in significant heterogeneity (Q 11.8 [5 d.f.], P = 0.03, I(2) = 57.7%). Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship of statin therapy to incident diabetes remains uncertain. Future statin trials should be designed to formally address this issue.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911203

Download citation: RISBibTeXText

PMID: 19794004

DOI: 10.2337/dc09-0738

Related references

Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiology and Drug Safety 25(10): 1131-1149, 2016

Statin Use And Risk Of Developing Diabetes In Cardiovascular Disease: Systematic Literature Review And Meta-Analysis. Value in Health 17(7): A478-A478, 2014

Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opinion on PharmacoTherapy 14(12): 1575-1584, 2014

Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis. Plos One 9(8): E104922-E104922, 2016

The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?. Progress in Cardiovascular Diseases 59(2): 145-152, 2016

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305(24): 2556-2564, 2011

A meta-analysis of passive smoking and risk of developing Type 2 Diabetes Mellitus. Diabetes Research and Clinical Practice 107(1): 9-14, 2015

Bilateral Earlobe Crease as a Marker of Premature Coronary Artery Disease. Cureus 10(5): E2616-E2616, 2018

The effect of day care exposure on the risk of developing type 1 diabetes: a meta-analysis of case-control studies. Diabetes Care 24(8): 1353-1358, 2001

Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes. Diabetologia 52(3): 394-397, 2008

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. American Journal of Cardiovascular Drugs 11(2): 115-128, 2012

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716): 735-742, 2010

Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis. Oncotarget (): -, 2016

Does statin therapy reduce the risk of stroke? A meta-analysis. Annales de Medecine Interne 152(3): 188-193, 2001

Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34(10): 2323-2328, 2012